Cancer-Related Mutations Identified in Primed Human Pluripotent Stem Cells

Yishai Avior; Elyad Lezmi; Kevin Eggan; Nissim Benvenisty

doi:10.1016/j.stem.2020.11.013

Cancer-Related Mutations Identified in Primed Human Pluripotent Stem Cells

Yishai Avior
, Elyad Lezmi
, Kevin Eggan
, Nissim Benvenisty^*

^*Corresponding author for this work

Department of Genetics

Research output: Contribution to journal › Letter › peer-review

33 Scopus citations

Original language	English
Pages (from-to)	10-11
Number of pages	2
Journal	Cell Stem Cell
Volume	28
Issue number	1
DOIs	https://doi.org/10.1016/j.stem.2020.11.013
State	Published - 7 Jan 2021

Bibliographical note

Funding Information:
N.B. is the Herbert Cohn Chair in Cancer Research. This work was partially supported by the US-Israel Binational Science Foundation (grant no. 2015089), the Israel Science Foundation (grant no. 494/17), The Rosetrees Trust, and the Azrieli Foundation (to N.B.). Y.A. and N.B. designed the original research. K.E. supplied the reference whole-exome sequencing. Y.A. established the bioinformatical pipeline and performed the original analysis. E.L and Y.A. reanalyzed the data and revised the pipeline. Y.A. E.L. and N.B. interpreted the results and together with K.E. prepared the manuscript. N.B. supervised the study and secured funding. N.B. is CSO of NewStem Ltd. K.E. is a founder of Q-State Biosciences, Quralis, and Enclear Therapies.

Funding Information:
N.B. is the Herbert Cohn Chair in Cancer Research. This work was partially supported by the US-Israel Binational Science Foundation (grant no. 2015089 ), the Israel Science Foundation (grant no. 494/17 ), The Rosetrees Trust , and the Azrieli Foundation (to N.B.).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.stem.2020.11.013

Cite this

@article{75a8bd53916942c39c95957600319d85,

title = "Cancer-Related Mutations Identified in Primed Human Pluripotent Stem Cells",

author = "Yishai Avior and Elyad Lezmi and Kevin Eggan and Nissim Benvenisty",

note = "Funding Information: N.B. is the Herbert Cohn Chair in Cancer Research. This work was partially supported by the US-Israel Binational Science Foundation (grant no. 2015089), the Israel Science Foundation (grant no. 494/17), The Rosetrees Trust, and the Azrieli Foundation (to N.B.). Y.A. and N.B. designed the original research. K.E. supplied the reference whole-exome sequencing. Y.A. established the bioinformatical pipeline and performed the original analysis. E.L and Y.A. reanalyzed the data and revised the pipeline. Y.A. E.L. and N.B. interpreted the results and together with K.E. prepared the manuscript. N.B. supervised the study and secured funding. N.B. is CSO of NewStem Ltd. K.E. is a founder of Q-State Biosciences, Quralis, and Enclear Therapies. Funding Information: N.B. is the Herbert Cohn Chair in Cancer Research. This work was partially supported by the US-Israel Binational Science Foundation (grant no. 2015089 ), the Israel Science Foundation (grant no. 494/17 ), The Rosetrees Trust , and the Azrieli Foundation (to N.B.). ",

year = "2021",

month = jan,

day = "7",

doi = "10.1016/j.stem.2020.11.013",

language = "אנגלית",

volume = "28",

pages = "10--11",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Cancer-Related Mutations Identified in Primed Human Pluripotent Stem Cells

AU - Avior, Yishai

AU - Lezmi, Elyad

AU - Eggan, Kevin

AU - Benvenisty, Nissim

N1 - Funding Information: N.B. is the Herbert Cohn Chair in Cancer Research. This work was partially supported by the US-Israel Binational Science Foundation (grant no. 2015089), the Israel Science Foundation (grant no. 494/17), The Rosetrees Trust, and the Azrieli Foundation (to N.B.). Y.A. and N.B. designed the original research. K.E. supplied the reference whole-exome sequencing. Y.A. established the bioinformatical pipeline and performed the original analysis. E.L and Y.A. reanalyzed the data and revised the pipeline. Y.A. E.L. and N.B. interpreted the results and together with K.E. prepared the manuscript. N.B. supervised the study and secured funding. N.B. is CSO of NewStem Ltd. K.E. is a founder of Q-State Biosciences, Quralis, and Enclear Therapies. Funding Information: N.B. is the Herbert Cohn Chair in Cancer Research. This work was partially supported by the US-Israel Binational Science Foundation (grant no. 2015089 ), the Israel Science Foundation (grant no. 494/17 ), The Rosetrees Trust , and the Azrieli Foundation (to N.B.).

PY - 2021/1/7

Y1 - 2021/1/7

UR - https://www.scopus.com/pages/publications/85098638970

U2 - 10.1016/j.stem.2020.11.013

DO - 10.1016/j.stem.2020.11.013

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 33321073

AN - SCOPUS:85098638970

SN - 1934-5909

VL - 28

SP - 10

EP - 11

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 1

ER -

Cancer-Related Mutations Identified in Primed Human Pluripotent Stem Cells

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this